Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Current Assets (2022 - 2025)

Phathom Pharmaceuticals (PHAT) has disclosed Current Assets for 4 consecutive years, with $229.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Current Assets fell 36.42% to $229.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $229.0 million, a 36.42% decrease, with the full-year FY2025 number at $229.0 million, down 36.42% from a year prior.
  • Current Assets was $229.0 million for Q4 2025 at Phathom Pharmaceuticals, up from $207.8 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $397.4 million in Q4 2023 to a low of $139.8 million in Q1 2023.
  • A 4-year average of $252.2 million and a median of $227.8 million in 2023 define the central range for Current Assets.
  • Peak YoY movement for Current Assets: soared 147.6% in 2023, then tumbled 44.42% in 2025.
  • Phathom Pharmaceuticals' Current Assets stood at $160.5 million in 2022, then surged by 147.6% to $397.4 million in 2023, then decreased by 9.38% to $360.1 million in 2024, then plummeted by 36.42% to $229.0 million in 2025.
  • Per Business Quant, the three most recent readings for PHAT's Current Assets are $229.0 million (Q4 2025), $207.8 million (Q3 2025), and $218.9 million (Q2 2025).